Sheena Jonathan sold $29K of NTRA

Sheena Jonathan sold 109 shares of Natera, Inc. (NTRA) at $267.99 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Aug 6, 2026, 1:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest disclosed fact is the director’s open-market sale of 109 shares at $267.9893 on 2026-08-03, totaling $29,210.83, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note the insider sale, but the 10b5-1 structure and small dollar value reduce expected market impact.

03

What to watch

The filing does not indicate intent beyond the plan; without context on prior sales cadence or total insider holdings changes over time, the signal is weak.

Relevance 2/10Novelty 3/10Timing: Filed 2026-08-05 for a sale dated 2026-08-03.

Background

The article is a SEC Form 4 insider transaction disclosure for Natera, Inc. (NTRA).

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera director Sheena Jonathan sold 109 shares in an open-market transaction at $267.9893 on 2026-08-03 under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move from this filing alone; any reaction is likely muted.

Evidence & confidence

The filing is a Form 4 insider sale, but it is explicitly tied to a pre-arranged 10b5-1 plan and the disclosed size is modest ($29.2K).

Market effects

No clear sector read-through from a single small 10b5-1 insider sale.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal risk management or valuation concerns, which some traders may still monitor.

Key entities

  • Natera, Inc.

    Company whose director insider sale is disclosed on Form 4.

  • Sheena Jonathan

    Director who executed the open-market sale under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMed

What's Next for Colorectal Cancer? A Major Announcement at OncoDaily

Natera announced a partnership with Agenus to use Signatera ctDNA testing in the Phase III ROBIN trial for colorectal cancer. The trial will compare neoadjuvant immunotherapy plus surgery to upfront surgery. Dr. Robert Lentz, Natera's Medical Director, highlighted the potential of ctDNA testing in treatment evaluation and decision-making.

$NTRAMed

Natera CFO Defends CEO Switch, Calls $6 Billion Revenue Target a “Way Station”

Natera CFO David Brophy defended the CEO transition and outlined long-term revenue targets. He estimated a $20B-$40B market opportunity for Signatera, with $1B revenue expected this year. Brophy also discussed competition, pricing, and market expansion into colorectal cancer screening and early detection tests. Natera (NASDAQ:NTRA) develops genetic testing and molecular diagnostics for various health applications.

$NTRAMed

Natera, Incyte Launch Phase 2 MRD-Guided Colorectal Cancer Study

Natera (NTRA) and Incyte (INCY) launched a Phase 2 study for colorectal cancer using Natera's Signatera test to identify high-risk patients. The trial will evaluate Incyte's INCA33890 immunotherapy in stage 2 or 3 patients post-treatment. Signatera will monitor patients for up to 12 months, with MRD-positive patients potentially enrolling. The study aims to improve outcomes by intervening earlier. NTRA closed at $320.39, up 3.13%.